For years, the biotech industry has poured billions into targeting epigenetic disease, only to run into the same wall. Most drugs go after catalytic pockets on enzymes. But those targets often exist in both healthy and diseased cells, making it incredibly difficult to achieve precision without unintended side effects.
That’s where SOSV portfolio company TippingPoint Biosciences is taking a fundamentally different approach with a new $4.5M Seed round led by SOSV and LKS Fund, with participation from a strong syndicate of investors and disease-focused foundations.
TippingPoint’s drug discovery platform targets epigenetic protein interfaces long considered “undruggable,” opening a new frontier in precision medicine. They do this by recreating disease-specific chromatin environments to reveal transient protein–protein interfaces that are unique to pathological states, unlocking highly selective and previously inaccessible targets within the epigenome.
Their first focus: Diffuse Intrinsic Pontine Glioma (DIPG), one of the deadliest pediatric brain cancers.
Uncategorized,rare disease,theraputicsrare disease,theraputics#TippingPoint #Raises #4.5M #Seed #Drug #Hidden #Epigenetic #Targets #Deadly #Pediatric #Brain #Cancer1774986018
